An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
复制标题
DOI：
10.1016/j.ygyno.2011.08.014
复制
发表时间：
2012-01-01
影响因子：
4.7
通讯作者：
Barakat, Richard R.
中科院分区：
文献类型：
--
作者：
Chi, Dennis S.;Musa, Fernanda;Barakat, Richard R.
Objective.最近的EORTC-NCIC随机试验比较了原发性减瘤手术（PDS）与新辅助化疗（NACT）治疗晚期上皮性卵巢癌（EOC），两组的中位无进展生存期（PFS）为12个月，总生存期（OS）为30个月。由于NACT具有相同的生存率和降低的发病率，许多人现在认为它是首选方法。我们使用相同的纳入标准，分析了在EORTC-NCIC试验进行的同一时间段内，在我们机构接受PDS治疗的患者的结局。我们确定了从1998年9月至2006年12月在我们机构接受晚期EOC初步治疗的所有患者。研究入选和排除标准与EORTC-NCIC试验相同。采用标准统计检验。在316例合格患者中，285例（90%）接受了PDS，31例（10%）因腹外疾病、医学合并症和/或高龄（>85岁）接受了NACT。在接受PDS的285名患者中，大多数患有卵巢癌（248，87%）; IIIC期疾病（249，87%）; 3级肿瘤（237，83%）;和浆液性组织学（249，87%）。最佳细胞还原（
Objective. The recent EORTC-NCIC randomized trial comparing primary debulking surgery (PDS) to neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian carcinoma (EOC) reported a median progression-free survival (PFS) of 12 months and overall survival (OS) of 30 months for both arms. Due to the equivalent survival and decreased morbidity with NACT, many now consider it the preferred approach. We analyzed the outcomes of patients treated with PDS at our institution during the same time period in which the EORTC-NCIC trial was conducted, using identical inclusion criteria.Methods. We identified all patients undergoing primary treatment for advanced EOC at our institution from 9/98-12/06. Study inclusion and exclusion criteria were identical to those of the EORTC-NCIC trial. Standard statistical tests were used.Results. Of 316 eligible patients, 285 (90%) underwent PDS and 31(10%) received NACT due to extra-abdominal disease, medical comorbidities, and/or advanced age (>85 years). Of the 285 patients who underwent PDS, most had carcinoma of ovarian origin (248, 87%); stage IIIC disease (249, 87%); grade 3 tumors (237, 83%); and serous histology (249,87%). Optimal cytoreduction (